Treatment with sodium-glucose cotransporter 2 inhibitor (SGLT2i) canagliflozin (100 mg/day) induced a spontaneous regression of HCC in a cirrhotic patient with T2DM, with a reduction in angiogenesis-related cytokines, such as angiopoietin-1/2 and platelet-derived growth factor-AA (PDGF-AA). This evidence concerns the gene ANGPT1 and type 2 diabetes mellitus.